<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36968793</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2731-4383</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>1</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Discover mental health</Title><ISOAbbreviation>Discov Ment Health</ISOAbbreviation></Journal><ArticleTitle>Overview of the potential use of fluvoxamine for COVID-19 and long COVID.</ArticleTitle><Pagination><StartPage>9</StartPage><MedlinePgn>9</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s44192-023-00036-3</ELocationID><Abstract><AbstractText>Coronavirus disease 2019 (COVID-19) has presented a serious worldwide threat to public health since its emergence in late 2019. From a safety point of view, drug repurposing has received particular attention. Several clinical studies have demonstrated that the use of fluvoxamine, a selective serotonin reuptake inhibitor with potent sigma-1 receptor agonism, in the early-stage of infection might be associated with the prevention of clinical deterioration in individuals with SARS-CoV-2 infection, although several reports have shown that a low dose of fluvoxamine may be ineffective. There is increasing evidence that SARS-CoV-2 can cross the blood-brain barrier, resulting in a number of psychiatric and neurologic symptoms in COVID-19 survivors. Importantly, about half of COVID-19 survivors experience a variety of long-term sequelae, including psychiatric and neurologic symptoms, known as long COVID. In this priority review, the author presents an overview of the potential use of fluvoxamine in the treatment of COVID-19 and long COVID.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba, 260-8670 Japan.</Affiliation><Identifier Source="GRID">grid.411500.1</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Discov Ment Health</MedlineTA><NlmUniqueID>9918350483906676</NlmUniqueID><ISSNLinking>2731-4383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antidepressants</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Fluvoxamine</Keyword><Keyword MajorTopicYN="N">Post-acute COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">Serotonin</Keyword><Keyword MajorTopicYN="N">Sigma-1 receptor</Keyword></KeywordList><CoiStatement>Competing interestsDr. Hashimoto is the inventor of filed patent applications on &#x201c;The use of R-Ketamine in the treatment of psychiatric diseases&#x201d;, &#x201c;(S)-norketamine and salt thereof as pharmaceutical&#x201d;, &#x201c;R-Ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder&#x201d;, &#x201c;Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases&#x201d;, and &#x201c;R-Ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder&#x201d; by the Chiba University. Dr. Hashimoto has also received speakers&#x2019; honoraria, consultant fee, or research support from Abbott, Boehringer-Ingelheim, Daiichi-Sankyo, Meiji Seika Pharma, Seikagaku Corporation, Dainippon-Sumitomo, Taisho, Otsuka, Murakami Farm and Perception Neuroscience.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>27</Day><Hour>3</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36968793</ArticleId><ArticleId IdType="pmc">PMC10029802</ArticleId><ArticleId IdType="doi">10.1007/s44192-023-00036-3</ArticleId><ArticleId IdType="pii">36</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. Myocarditis cases reported after mRN-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA. 2022;327(4):331&#x2013;340. doi: 10.1001/jama.2021.24110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.24110</ArticleId><ArticleId IdType="pmc">PMC8790664</ArticleId><ArticleId IdType="pubmed">35076665</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlstad &#xd8;, Hovi P, Husby A, H&#xe4;rk&#xe4;nen T, Selmer RM, Pihlstr&#xf6;m N, et al. SARS-CoV-2 vaccination and mycarditis in a Nordic cohort study of 23 million residents. JAMA Cardiol. 2022;7(6):600&#x2013;612. doi: 10.1001/jamacardio.2022.0583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2022.0583</ArticleId><ArticleId IdType="pmc">PMC9021987</ArticleId><ArticleId IdType="pubmed">35442390</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry RJ, Tamborska A, Singh B, Craven B, Marigold R, Arthur-Farraj P, et al. Cerebral venous thrombosis after vaccination against. Lancet. 2021;398(10306):1147&#x2013;1156. doi: 10.1016/S0140-6736(21)01608-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01608-1</ArticleId><ArticleId IdType="pmc">PMC8346241</ArticleId><ArticleId IdType="pubmed">34370972</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavord S, Hunt BJ, Horner D, Bewley S, Karpusheff J, Guideline Committee Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance. BMJ. 2021;375:n2195. doi: 10.1136/bmj.n2195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2195</ArticleId><ArticleId IdType="pubmed">34598931</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YE, Huh K, Park YJ, Peck KR, Jung J. Association between vaccination and acute myocardial infarction and ischemic stroke after COVID-19 infection. JAMA. 2022;328(9):887&#x2013;889. doi: 10.1001/jama.2022.12992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.12992</ArticleId><ArticleId IdType="pmc">PMC9449799</ArticleId><ArticleId IdType="pubmed">35867050</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanou MI, Palaiodimou L, Aguiar de Sousa D, Theodorou A, Bakola E, Katsaros DE, et al. Acute arterial ischemic stroke following COVID-19 vaccination: a systematic review and meta-analysis. Neurology. 2022 doi: 10.1212/WNL.0000000000200996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000200996</ArticleId><ArticleId IdType="pubmed">36002319</ArticleId></ArticleIdList></Reference><Reference><Citation>Brazil R. How your first brush with COVID warps your immunity. Nature. 2023;613(7944):428&#x2013;430. doi: 10.1038/d41586-023-00086-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-023-00086-1</ArticleId><ArticleId IdType="pubmed">36653572</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydillo T, Rombauts A, Stadlbauer D, Aslam S, Abelenda-Alonso G, Escalera A, et al. Immunological imprinting of the antibody response in COVID-19 patients. Nat Commun. 2021;12(1):3781. doi: 10.1038/s41467-021-23977-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23977-1</ArticleId><ArticleId IdType="pmc">PMC8213790</ArticleId><ArticleId IdType="pubmed">34145263</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K. Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor. Eur Arch Psychiatry Clin Neurosci. 2021;271(1):249&#x2013;258. doi: 10.1007/s00406-020-01231-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00406-020-01231-x</ArticleId><ArticleId IdType="pmc">PMC7785036</ArticleId><ArticleId IdType="pubmed">33403480</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto Y, Suzuki T, Hashimoto K. Old drug fluvoxamine, new hope for COVID-19. Eur Arch Psychiatry Clin Neurosci. 2022;272(1):161&#x2013;163. doi: 10.1007/s00406-021-01326-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00406-021-01326-z</ArticleId><ArticleId IdType="pmc">PMC8412866</ArticleId><ArticleId IdType="pubmed">34476589</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto Y, Suzuki T, Hashimoto K. Mechanisms of action of fluvoxamine for COVID-19: a historical review. Mol Psychiatry. 2022;27(4):1898&#x2013;1907. doi: 10.1038/s41380-021-01432-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01432-3</ArticleId><ArticleId IdType="pmc">PMC8739627</ArticleId><ArticleId IdType="pubmed">34997196</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Xie B, Hashimoto K. Current status of potential therapeutic candidates for the COVID-19 crisis. Brain Behav Immun. 2020;87:59&#x2013;73. doi: 10.1016/j.bbi.2020.04.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.04.046</ArticleId><ArticleId IdType="pmc">PMC7175848</ArticleId><ArticleId IdType="pubmed">32334062</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng YL, Salim CK, Chu JJH. Drug repurposing for COVID-19: approaches, challenges and promising candidates. Pharmacol Ther. 2021;228:107930. doi: 10.1016/j.pharmthera.2021.107930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2021.107930</ArticleId><ArticleId IdType="pmc">PMC8220862</ArticleId><ArticleId IdType="pubmed">34174275</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan P. Repurposing drugs for treatment of COVID-19. Lancet Respir Med. 2021;9(7):e63. doi: 10.1016/S2213-2600(21)00270-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00270-8</ArticleId><ArticleId IdType="pmc">PMC8175045</ArticleId><ArticleId IdType="pubmed">34090608</ArticleId></ArticleIdList></Reference><Reference><Citation>Fico G, Isayeva U, De Prisco M, Oliva V, Sol&#xe8; B, Montejo L, et al. Psychotropic drug repurposing for COVID-19: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2023;66:30&#x2013;44. doi: 10.1016/j.euroneuro.2022.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2022.10.004</ArticleId><ArticleId IdType="pmc">PMC9581805</ArticleId><ArticleId IdType="pubmed">36399837</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenze E, Mattar C, Zorumski CF, Zorumski CF, Stevens A, Schweiger J, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19. A randomized clinical trial. JAMA. 2020;324(22):2292&#x2013;2300. doi: 10.1001/jama.2020.22760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.22760</ArticleId><ArticleId IdType="pmc">PMC7662481</ArticleId><ArticleId IdType="pubmed">33180097</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondratiuk AL, Pillay TD, Kon OM, Lalvani A. A conceptual framework to accelerate the clinical impact of evolving research into long COVID. Lancet Infect Dis. 2021;21(6):756&#x2013;757. doi: 10.1016/S1473-3099(21)00136-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00136-5</ArticleId><ArticleId IdType="pmc">PMC8062085</ArticleId><ArticleId IdType="pubmed">33894903</ArticleId></ArticleIdList></Reference><Reference><Citation>Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C, Ballouz T, et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328(16):1604&#x2013;1615. doi: 10.1001/jama.2022.18931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorman EA, O'Kane CM, McAuley DF. Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequalae, and management. Lancet. 2022;400(10358):1157&#x2013;1170. doi: 10.1016/S0140-6736(22)01439-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01439-8</ArticleId><ArticleId IdType="pubmed">36070788</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case Definition Working Group on Post-COVID-19 Condition A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng N, Zhao YM, Yan W, Li C, Lu QD, Liu L, et al. A systematic review and meta-analysis of long-term physical and mental sequelae of COVID-19 pandemic: call for research priority and action. Mol Psychiatry. 2023;28(1):423&#x2013;433. doi: 10.1038/s41380-022-01614-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01614-7</ArticleId><ArticleId IdType="pmc">PMC9168643</ArticleId><ArticleId IdType="pubmed">35668159</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaffer L. Lots of long COVID treatment leads, but few are proven. Proc Natl Acad Sci USA. 2022;119(36):e2213524119. doi: 10.1073/pnas.2213524119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2213524119</ArticleId><ArticleId IdType="pmc">PMC9456722</ArticleId><ArticleId IdType="pubmed">36048910</ArticleId></ArticleIdList></Reference><Reference><Citation>Adnot S, Houssaini A, Abid S, Marcos E, Amsellem V. Serotonin transporter and serotonin receptors. Handb Exp Pharmacol. 2013;218:365&#x2013;380. doi: 10.1007/978-3-642-38664-0_15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-642-38664-0_15</ArticleId><ArticleId IdType="pubmed">24092348</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K, Goromaru T. High-affinity [3H]6-nitroquipazine binding to the 5-hydroxytryptamine transport system in rat lung. Biochem Pharmacol. 1991;41(11):1679&#x2013;1682. doi: 10.1016/0006-2952(91)90169-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-2952(91)90169-6</ArticleId><ArticleId IdType="pubmed">1828346</ArticleId></ArticleIdList></Reference><Reference><Citation>Takano A, Suhara T, Sudo Y, Inoue M, Hashimoto K, Zhang MR, et al. Comparative evaluation of two serotonin transporter ligands in the human brain: [11C](+)McN5652 and [11C]cyanoimipramine. Eur J Nucl Med. 2002;29(10):1289&#x2013;1297. doi: 10.1007/s00259-002-0884-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-002-0884-4</ArticleId><ArticleId IdType="pubmed">12271409</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K, Goromaru T. High-affinity binding of [3H]6-nitroquipazine to 5-hydroxytryptamine transporter in human platelets. Eur J Pharmacol. 1990;187(3):295&#x2013;302. doi: 10.1016/0014-2999(90)90356-b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-2999(90)90356-b</ArticleId><ArticleId IdType="pubmed">2073917</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost. 2004;91(1):119&#x2013;128. doi: 10.1160/TH03-05-0330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH03-05-0330</ArticleId><ArticleId IdType="pubmed">14691577</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercado CP, Killic F. Molecular mechanisms of SERT in platelets: regulation of plasma serotonin levels. Mol Interv. 2010;10(4):231&#x2013;241. doi: 10.1124/mi.10.4.6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mi.10.4.6</ArticleId><ArticleId IdType="pmc">PMC2965611</ArticleId><ArticleId IdType="pubmed">20729489</ArticleId></ArticleIdList></Reference><Reference><Citation>Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry. 2001;50(5):345&#x2013;350. doi: 10.1016/s0006-3223(01)01145-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0006-3223(01)01145-3</ArticleId><ArticleId IdType="pubmed">11543737</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohgi Y, Futamura T, Kikuchi T, Hashimoto K. Effects of antidepressants on alterations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav. 2013;103(4):853&#x2013;859. doi: 10.1016/j.pbb.2012.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pbb.2012.12.003</ArticleId><ArticleId IdType="pubmed">23262300</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C, Zhang JC, Yao W, Ren Q, Yang C, Ma M, et al. Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-alpha, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav. 2016;144:7&#x2013;12. doi: 10.1016/j.pbb.2016.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pbb.2016.02.005</ArticleId><ArticleId IdType="pubmed">26892759</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K. Inflammatory biomarkers as differential predictors of antidepressant response. Int J Mol Sci. 2015;16(4):7796&#x2013;7801. doi: 10.3390/ijms16047796.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms16047796</ArticleId><ArticleId IdType="pmc">PMC4425050</ArticleId><ArticleId IdType="pubmed">25856677</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Wang R, Liu L, Qiao D, Baldwin DS, Hou R. Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: a systematic review and meta-analysis. Brain Behav Immun. 2019;79:24&#x2013;38. doi: 10.1016/j.bbi.2019.02.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2019.02.021</ArticleId><ArticleId IdType="pubmed">30797959</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoertel N, S&#xe1;nchez-Rico M, Vernet R, Beeker N, Jannot AS, Neuraz A, et al. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry. 2021;26(9):5199&#x2013;5212. doi: 10.1038/s41380-021-01021-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01021-4</ArticleId><ArticleId IdType="pubmed">33536545</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci USA. 1996;93(15):8072&#x2013;8077. doi: 10.1073/pnas.93.15.8072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.93.15.8072</ArticleId><ArticleId IdType="pmc">PMC38877</ArticleId><ArticleId IdType="pubmed">8755605</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell. 2007;131(3):596&#x2013;610. doi: 10.1016/j.cell.2007.08.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.08.036</ArticleId><ArticleId IdType="pubmed">17981125</ArticleId></ArticleIdList></Reference><Reference><Citation>Narita N, Hashimoto K, Tomitaka S, Minabe Y. Interaction of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol. 1996;307(1):117&#x2013;119. doi: 10.1016/0014-2999(96)00254-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-2999(96)00254-3</ArticleId><ArticleId IdType="pubmed">8831113</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology. 2007;32(3):514&#x2013;521. doi: 10.1038/sj.npp.1301047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.npp.1301047</ArticleId><ArticleId IdType="pubmed">16495935</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishima T, Fujita Y, Kohno M, Kunitachi S, Hotio M, Takatsu Y, et al. Improvement of phencyclidine-induced cognitive deficits in mice by subsequent subchronic administration of fluvoxamine, but not sertraline. Open Clin Chem J. 2009;2:7&#x2013;11. doi: 10.2174/1874241600902010007.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1874241600902010007</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura T, Ishima T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS ONE. 2008;3(7):e2558. doi: 10.1371/journal.pone.0002558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0002558</ArticleId><ArticleId IdType="pmc">PMC2435603</ArticleId><ArticleId IdType="pubmed">18596927</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishima T, Fujita Y, Hashimoto K. Interactions of new antidepressants with sigma-1 receptor chaperons and their potentiation of neurite outgrowth in PC12 cells. Eur J Pharmacol. 2014;727:167&#x2013;173. doi: 10.1016/j.ejphar.2014.01.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2014.01.064</ArticleId><ArticleId IdType="pubmed">24508523</ArticleId></ArticleIdList></Reference><Reference><Citation>Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol. 2010;25(3):193&#x2013;200. doi: 10.1002/hup.1106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hup.1106</ArticleId><ArticleId IdType="pubmed">20373470</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog Neurobiol. 2013;100:15&#x2013;29. doi: 10.1016/j.pneurobio.2012.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2012.09.001</ArticleId><ArticleId IdType="pubmed">23044468</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K. Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication. J Pharmacol Sci. 2015;127(1):6&#x2013;9. doi: 10.1016/j.jphs.2014.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jphs.2014.11.010</ArticleId><ArticleId IdType="pubmed">25704012</ArticleId></ArticleIdList></Reference><Reference><Citation>Albayrak Y, Hashimoto K. Sigma-1 receptor agonists and their clinical implication in neuropsychiatric disorders. Adv Exp Med Biol. 2017;964:153&#x2013;161. doi: 10.1007/978-3-319-50174-1_11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-50174-1_11</ArticleId><ArticleId IdType="pubmed">28315270</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DA, Seki SM, Fern&#xe1;ndez-Casta&#xf1;eda A, Beiter RM, Eccles JD, Woodfolk JA, et al. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med. 2019;11(478):eaau5266. doi: 10.1126/scitranslmed.aau5266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aau5266</ArticleId><ArticleId IdType="pmc">PMC6936250</ArticleId><ArticleId IdType="pubmed">30728287</ArticleId></ArticleIdList></Reference><Reference><Citation>Friesland M, Mingorance L, Chung J, Chisari FV, Gastaminza P. Sigma-1 receptor regulates early steps of viral RNA replication at the inset of hepatitis C virus infection. J Virol. 2013;87(11):6377&#x2013;6390. doi: 10.1128/JVI.03557-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03557-12</ArticleId><ArticleId IdType="pmc">PMC3648129</ArticleId><ArticleId IdType="pubmed">23536676</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasallo C, Gastaminza P. Cellular stress response in hepatitis C virus infection: mastering a two-edged sword. Virus Res. 2015;209:100&#x2013;117. doi: 10.1016/j.virusres.2015.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2015.03.013</ArticleId><ArticleId IdType="pubmed">25836277</ArticleId></ArticleIdList></Reference><Reference><Citation>Vela JM. Repurposing sigma-1 receptor ligands for COVID-19 therapy? Front Pharmacol. 2020;11:582310. doi: 10.3389/fphar.2020.582310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.582310</ArticleId><ArticleId IdType="pmc">PMC7751758</ArticleId><ArticleId IdType="pubmed">33364957</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583(7816):459&#x2013;468. doi: 10.1038/s41586-020-2286-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2286-9</ArticleId><ArticleId IdType="pmc">PMC7431030</ArticleId><ArticleId IdType="pubmed">32353859</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon DE, Hiatt J, Bouhaddou M, Rezelj VV, Ulferts S, Braberg H, et al. Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science. 2020;370(6521):eabe9403. doi: 10.1126/science.abe9403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe9403</ArticleId><ArticleId IdType="pmc">PMC7808408</ArticleId><ArticleId IdType="pubmed">33060197</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukhatme VP, Reiersen AM, Vayttaden SJ, Sykhatme W. Fluvoxamine: a review of its mechanisms of actions and its role in COVID-19. Front Pharmacol. 2021;12:652688. doi: 10.3389/fphar.2021.652688.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.652688</ArticleId><ArticleId IdType="pmc">PMC8094534</ArticleId><ArticleId IdType="pubmed">33959018</ArticleId></ArticleIdList></Reference><Reference><Citation>Brimson JM, Prasanth MI, Malar DS, Brimson S, Thitilertdecha P, Tencomnao T. Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: the possible role of the sigma-1 receptor and autophagy. Expert Opin Ther Targets. 2021;25(6):435&#x2013;449. doi: 10.1080/14728222.2021.1952987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2021.1952987</ArticleId><ArticleId IdType="pmc">PMC8290373</ArticleId><ArticleId IdType="pubmed">34236922</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Wang A, Wu Y, Gulbins E, Grassm&#xe9; H, Zhao Z. Acid sphingomyelinase-ceramide system in bacterial infections. Cell Physiol Biochem. 2019;52(2):280&#x2013;301. doi: 10.33594/000000021.</Citation><ArticleIdList><ArticleId IdType="doi">10.33594/000000021</ArticleId><ArticleId IdType="pubmed">30816675</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckmann N, Becker KA. Ceramide and related molecules in viral infections. Int J Mol Sci. 2021;22(11):5676. doi: 10.3390/ijms22115676.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22115676</ArticleId><ArticleId IdType="pmc">PMC8197834</ArticleId><ArticleId IdType="pubmed">34073578</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf6;rnquist K, Asghar MY, Srinivasan V, Korhonen L, Lindholm D. Sphingolipids as modulators of SARS-CoV-2 infection. Front Cell Dev Biol. 2021;9:689854. doi: 10.3389/fcell.2021.689854.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.689854</ArticleId><ArticleId IdType="pmc">PMC8245774</ArticleId><ArticleId IdType="pubmed">34222257</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornhuber J, Tripal P, Reichel M, M&#xfc;hle C, Rhein C, Muehlbacher M, et al. Functional inhibitors of acid sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem. 2010;26(1):9&#x2013;20. doi: 10.1159/000315101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000315101</ArticleId><ArticleId IdType="pubmed">20502000</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornhuber J, Hoertel N, Gulbins E. The acid sphingomyelinase/ceramide system in COVID-19. Mol Psychiatry. 2022;27(1):307&#x2013;314. doi: 10.1038/s41380-021-01309-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01309-5</ArticleId><ArticleId IdType="pmc">PMC8488928</ArticleId><ArticleId IdType="pubmed">34608263</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, et al. Identification of novel functional inhibitors of acid sphingomyelinase. PLoS ONE. 2011;6(8):e23852. doi: 10.1371/journal.pone.0023852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0023852</ArticleId><ArticleId IdType="pmc">PMC3166082</ArticleId><ArticleId IdType="pubmed">21909365</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulbins E, Palmada M, Reichel M, L&#xfc;th A, B&#xf6;hmer C, Amato D, et al. Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs. Nat Med. 2013;19(7):934&#x2013;938. doi: 10.1038/nm.3214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3214</ArticleId><ArticleId IdType="pubmed">23770692</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulbins A, Schumacher F, Becker KA, Wilker B, Soddemann M, Boldrin F, et al. Antidepressants act by inducing autophagy controlled by sphingomyelin-ceramide. Mol Psychiatry. 2018;23(12):2324&#x2013;2346. doi: 10.1038/s41380-018-0090-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0090-9</ArticleId><ArticleId IdType="pmc">PMC6294742</ArticleId><ArticleId IdType="pubmed">30038230</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoertel N, S&#xe1;nchez-Rico M, Gulbins E, Kornhuber J, Carpinteiro A, Lenze EJ, et al. Association between FIASMAs and reduced risk of intubation or death in individuals hospitalized for severe COVID-19: an observational multicenter study. Clin Pharmacol Ther. 2021;110(6):1498&#x2013;1511. doi: 10.1002/cpt.2317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.2317</ArticleId><ArticleId IdType="pmc">PMC8239599</ArticleId><ArticleId IdType="pubmed">34050932</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, et al. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. Biol Psychiatry. 2007;62(8):878&#x2013;883. doi: 10.1016/j.biopsych.2007.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2007.04.001</ArticleId><ArticleId IdType="pubmed">17662961</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenze E. Fluvoxamine for early treatment of Covid-19 (Stop Covid 2). ClinicalTrials.gov Identifier: NCT04668950.</Citation></Reference><Reference><Citation>Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect Dis. 2021;8(2):ofab050. doi: 10.1093/ofid/ofab050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab050</ArticleId><ArticleId IdType="pmc">PMC7888564</ArticleId><ArticleId IdType="pubmed">33623808</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis G, Moreira Silva EADS, Medeiros Silva DC, Thabane L, Milagres AC, Ferreira TS, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalization among patients with COVID-19: the TOGETHER randomized, platform clinical trial. Lancet Glob Health. 2022;10(1):e42&#x2013;e51. doi: 10.1016/S2214-109X(21)00448-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(21)00448-4</ArticleId><ArticleId IdType="pmc">PMC8550952</ArticleId><ArticleId IdType="pubmed">34717820</ArticleId></ArticleIdList></Reference><Reference><Citation>Calusic M, Marcec R, Luksa L, Jurkovic I, Kovac N, Mihaljevic S, et al. Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls. Bri J Clin Pharmacol. 2022;88(5):2065&#x2013;2073. doi: 10.1111/bcp.15126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.15126</ArticleId><ArticleId IdType="pmc">PMC8653355</ArticleId><ArticleId IdType="pubmed">34719789</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskotsky T, Maric I, Tang A, Oskotsky B, Wong RJ, Aghaeepour N, et al. Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants. JAMA Netw Open. 2021;4(11):e2133090. doi: 10.1001/jamanetworkopen.2021.33090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.33090</ArticleId><ArticleId IdType="pmc">PMC8593759</ArticleId><ArticleId IdType="pubmed">34779847</ArticleId></ArticleIdList></Reference><Reference><Citation>Pineda E, Singh J, Pineda MV, Umanzor JG, Baires F, Benitez LG, et al. Impact of fluvoxamine on outpatient treatment of COVID-19 in Honduras in a prospective observational real-world study. Front Pharmacol. 2022;13:1054644. doi: 10.3389/fphar.2022.1054644.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.1054644</ArticleId><ArticleId IdType="pmc">PMC9748291</ArticleId><ArticleId IdType="pubmed">36532727</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo H, Kim H, Bae S, Park S, Chung H, Sung HS, et al. Fluvoxamine treatment of patients with symptomatic COVID-19 in a community treatment center: a preliminary result of randomized controlled trial. Infect Chemother. 2022;54(1):102&#x2013;113. doi: 10.3947/ic.2021.0142.</Citation><ArticleIdList><ArticleId IdType="doi">10.3947/ic.2021.0142</ArticleId><ArticleId IdType="pmc">PMC8987178</ArticleId><ArticleId IdType="pubmed">35384422</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante CT, Huling JD, Tignanelli CJ, Buse JB, Liebovitz DM, Nicklas JM, et al. Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19. N Engl J Med. 2022;387(7):599&#x2013;610. doi: 10.1056/NEJMoa2201662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2201662</ArticleId><ArticleId IdType="pmc">PMC9945922</ArticleId><ArticleId IdType="pubmed">36070710</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy MW, Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Felker GM, et al. Effect of fluvoxamine vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2023;329(4):296&#x2013;305. doi: 10.1001/jama.2022.24100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.24100</ArticleId><ArticleId IdType="pmc">PMC9857647</ArticleId><ArticleId IdType="pubmed">36633838</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhimraj A, Gallagher JC. Lack of benefit of fluvoxamine for COVID-19. JAMA. 2023;329(4):291&#x2013;292. doi: 10.1001/jama.2022.23954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.23954</ArticleId><ArticleId IdType="pubmed">36633871</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz AD, Baweja R. Protective effect of fluvoxamine for COVID-19 in obsessive&#x2013;compulsive disorder: a real-world case-control study. Prim Care Comp CNS Disord. 2022;24(5):22br03337. doi: 10.4088/PCC.22br03337.</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/PCC.22br03337</ArticleId><ArticleId IdType="pubmed">36206376</ArticleId></ArticleIdList></Reference><Reference><Citation>Puelles VG, L&#xfc;tgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, et al. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med. 2020;383(6):590&#x2013;592. doi: 10.1056/NEJMc2011400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2011400</ArticleId><ArticleId IdType="pmc">PMC7240771</ArticleId><ArticleId IdType="pubmed">32402155</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon IH, Normandin E, Bhattacharyya S, Mukerji SS, Keller K, Ali AS, et al. Neurological features of Covid-19. N Engl J Med. 2020;383(10):989&#x2013;992. doi: 10.1056/NEJMc2019373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2019373</ArticleId><ArticleId IdType="pmc">PMC7304421</ArticleId><ArticleId IdType="pubmed">32530583</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhea EM, Logsdon AF, Hansen KM, Williams LM, Reed MJ, Baumann KK, et al. The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice. Nat Neurosci. 2021;24(3):368&#x2013;378. doi: 10.1038/s41593-020-00771-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00771-8</ArticleId><ArticleId IdType="pmc">PMC8793077</ArticleId><ArticleId IdType="pubmed">33328624</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Zhou L, Bao L, Liu J, Zhu H, Lv Q, et al. SAES-CoV-2 crosses the blood&#x2013;brain barrier accompanied with basement membrane disruption without tight junctions alteration. Signal Transduct Target. 2021;6(1):337. doi: 10.1038/s41392-021-00719-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00719-9</ArticleId><ArticleId IdType="pmc">PMC8419672</ArticleId><ArticleId IdType="pubmed">34489403</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrovszki D, Walter FR, Vigh JP, Kocsis A, Valkai S, Deli MA, D&#xe9;r A. Penetration of the SARS-CoV-2 spike protein across the blood-brain barrier, as revealed by a combination of a human cell culture model system and optical biosensing. Biomedicines. 2022;10(1):188. doi: 10.3390/biomedicines10010188.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10010188</ArticleId><ArticleId IdType="pmc">PMC8773803</ArticleId><ArticleId IdType="pubmed">35052867</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604(7907):697&#x2013;707. doi: 10.1038/s41586-022-04569-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04569-5</ArticleId><ArticleId IdType="pmc">PMC9046077</ArticleId><ArticleId IdType="pubmed">35255491</ArticleId></ArticleIdList></Reference><Reference><Citation>Sollmann N, Beer AJ, Kirchhoff F. SARS-CoV-2 infection and the brain: direct evidence for brain changes in milder cases. Signal Transduct Target Ther. 2022;7(1):230. doi: 10.1038/s41392-022-01072-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01072-1</ArticleId><ArticleId IdType="pmc">PMC9272648</ArticleId><ArticleId IdType="pubmed">35817774</ArticleId></ArticleIdList></Reference><Reference><Citation>Song E, Zhang C, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med. 2021;218(3):e20202135. doi: 10.1084/jem.20202135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20202135</ArticleId><ArticleId IdType="pmc">PMC7808299</ArticleId><ArticleId IdType="pubmed">33433624</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein SR, Ramelli SC, Grazioli A, Chung JY, Singh M, Yinda CK, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612(7941):758&#x2013;763. doi: 10.1038/s41586-022-05542-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05542-y</ArticleId><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020;87:18&#x2013;22. doi: 10.1016/j.bbi.2020.03.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.03.031</ArticleId><ArticleId IdType="pmc">PMC7146689</ArticleId><ArticleId IdType="pubmed">32240762</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson MA, Rhea EM, Knopp RC, Banks WA. Interactions of SARS-CoV-2 with the blood&#x2013;brain barrier. Int J Mol Sci. 2021;22(5):2681. doi: 10.3390/ijms22052681.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22052681</ArticleId><ArticleId IdType="pmc">PMC7961671</ArticleId><ArticleId IdType="pubmed">33800954</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldfield PR, Hibberd J, Bridle BW. How does severe acute respiratory syndrome-coronavirus-2 affect the brain and its implications for the vaccines currently in use. Vaccines (Basel) 2021;10(1):1. doi: 10.3390/vaccines10010001.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10010001</ArticleId><ArticleId IdType="pmc">PMC8780773</ArticleId><ArticleId IdType="pubmed">35062662</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldrini M, Canoll PD, Klein RS. How COVID-19 affects the brain. JAMA Psychiat. 2021;78(6):682&#x2013;683. doi: 10.1001/jamapsychiatry.2021.0500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2021.0500</ArticleId><ArticleId IdType="pmc">PMC9894299</ArticleId><ArticleId IdType="pubmed">33769431</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC. Could SARS-CoV-2 spike protein be responsible for long-COVID syndrome? Mol Neurobiol. 2022;59(3):1850&#x2013;1861. doi: 10.1007/s12035-021-02696-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-021-02696-0</ArticleId><ArticleId IdType="pmc">PMC8757925</ArticleId><ArticleId IdType="pubmed">35028901</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021;4(10):e2128568. doi: 10.1001/jamanetworkopen.2021.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendation. Nat Rev Microbiol. 2023 doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Koc HC, Xiao J, Liu W, Li Y, Chen G. Long COVID and its management. Int J Biol Sci. 2022;18(12):4768&#x2013;4780. doi: 10.7150/ijbs.75056.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.75056</ArticleId><ArticleId IdType="pmc">PMC9305273</ArticleId><ArticleId IdType="pubmed">35874958</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidky H, Sahner DK, Girvin AT, Hotaling N, Michael SG, Kurilla MG, et al. Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19. medRxiv. 2022 doi: 10.1101/2022.11.09.22282142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.11.09.22282142</ArticleId><ArticleId IdType="pmc">PMC10839808</ArticleId><ArticleId IdType="pubmed">38318198</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenton C, Lee A. Antidepressants with anti-inflammatory properties may be useful in long COVID depression. Drugs Ther Perspect. 2023;39(2):65&#x2013;70. doi: 10.1007/s40267-022-00975-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40267-022-00975-x</ArticleId><ArticleId IdType="pmc">PMC9742030</ArticleId><ArticleId IdType="pubmed">36532316</ArticleId></ArticleIdList></Reference><Reference><Citation>Khani E, Entezari-Maleki T. Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists. Mol Psychiatry. 2022;27(9):3562. doi: 10.1038/s41380-022-01545-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01545-3</ArticleId><ArticleId IdType="pmc">PMC8985056</ArticleId><ArticleId IdType="pubmed">35388182</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto Y, Suzuki T, Hashimoto K. Comments to &#x201c;Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists&#x201d; by Khani and Entezari-Maleki. Mol Psychiatry. 2022;27(9):3563&#x2013;3564. doi: 10.1038/s41380-022-01546-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01546-2</ArticleId><ArticleId IdType="pmc">PMC8985059</ArticleId><ArticleId IdType="pubmed">35388183</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo CM, Harari O, Chernecki C, Thorlund K, Forrest JI. Fluvoxamine for the early treatment of COVID-19: a meta-analysis of randomized clinical trials. Am J Trop Med Hyg. 2022;106(5):1315&#x2013;1320. doi: 10.4269/ajtmh.21-1310.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.21-1310</ArticleId><ArticleId IdType="pmc">PMC9128689</ArticleId><ArticleId IdType="pubmed">35263710</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhuta S, Khokher W, Kesireddy N, Iftikhar S, Beran A, Mhanna M, et al. Fluvoxamine in nonhospitalized patients with acute COVID-19 infection and the lack of efficacy in reducing rates of hospitalization, mechanical ventilation, and mortality in placebo-controlled trials: a systematic review and meta-analysis. Am J Ther. 2022;29(3):e298&#x2013;e304. doi: 10.1097/MJT.0000000000001496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MJT.0000000000001496</ArticleId><ArticleId IdType="pubmed">35383578</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee TC, Vigod S, Bortolussi-Courval &#xc9;, Hanula R, Boulware DR, Lenze EJ, et al. Fluvoxamine for outpatients management of COVID-19 to prevent hospitalization: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(4):e226269. doi: 10.1001/jamanetworkopen.2022.6269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.6269</ArticleId><ArticleId IdType="pmc">PMC8987902</ArticleId><ArticleId IdType="pubmed">35385087</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheema HA, Jafar U, Elrashedy AA, Shahid A, Awan RU, Ehsan M, et al. Efficacy and safety of fluvoxamine for the treatment of COVID-19 patients. J Infect. 2022;85(6):702&#x2013;769. doi: 10.1016/j.jinf.2022.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2022.10.012</ArticleId><ArticleId IdType="pmc">PMC9558771</ArticleId><ArticleId IdType="pubmed">36244547</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu LC, Chao CM, Chang SP, Lan SH, Lai CC. Effect of fluvoxamine on outcomes of nonhospitalized patients with COVID-19: a systematic review and meta-analysis. J Infect Public Health. 2022;15(11):1259&#x2013;1264. doi: 10.1016/j.jiph.2022.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2022.10.010</ArticleId><ArticleId IdType="pmc">PMC9556767</ArticleId><ArticleId IdType="pubmed">36272390</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcec R, Dodig VM, Likic R. A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference. J Infect. 2023;86(2):154&#x2013;225. doi: 10.1016/j.jinf.2022.11.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2022.11.011</ArticleId><ArticleId IdType="pmc">PMC9673087</ArticleId><ArticleId IdType="pubmed">36403698</ArticleId></ArticleIdList></Reference><Reference><Citation>Trkulja V. There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: a comment on two recent meta-analyses advocating its use. J Infect. 2023;86(2):154&#x2013;225. doi: 10.1016/j.jinf.2022.11.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2022.11.016</ArticleId><ArticleId IdType="pmc">PMC9691281</ArticleId><ArticleId IdType="pubmed">36436621</ArticleId></ArticleIdList></Reference><Reference><Citation>Trkulja V. Why we should not recommend or offer fluvoxamine to COVID-19 patients? Eur J Clin Pharmacol. 2023;79(2):321&#x2013;322. doi: 10.1007/s00228-022-03447-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-022-03447-3</ArticleId><ArticleId IdType="pmc">PMC9780092</ArticleId><ArticleId IdType="pubmed">36550263</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J, Rayner D, Ba Ramaraju H, Abbas U, Carcia C, Heybati K, et al. Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis. Clin Microbiol Infect. 2023 doi: 10.1016/j.cmi.2023.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2023.01.010</ArticleId><ArticleId IdType="pmc">PMC9841740</ArticleId><ArticleId IdType="pubmed">36657488</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirenga BJ, Mugenyi L, S&#xe1;nchez-Rico M, Kyobe H, Muttamba W, Mugume R, et al. Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study. Mol Psychiatry. 2023;1&#x2013;8. 10.1038/s41380-023-02004-3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9982784</ArticleId><ArticleId IdType="pubmed">36869228</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahdi M, Herm&#xe1;n L, R&#xe9;thelyi JM, B&#xe1;lint BL. Potential role of the antidepressants fluoxetine and fluvoxamine in the treatment of COVID-19. Int J Mol Sci. 2022;23(7):3812. doi: 10.3390/ijms23073812.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23073812</ArticleId><ArticleId IdType="pmc">PMC8998734</ArticleId><ArticleId IdType="pubmed">35409171</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills FP, Reis G, Wilson LA, Thorlund K, Forrest JI, Guo CM, et al. Early treatment with fluvoxamine among patients with COVID-19: a cost-consequence model. Am J Trop Med Hyg. 2022;108(1):101&#x2013;106. doi: 10.4269/ajtmh.22-0106.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.22-0106</ArticleId><ArticleId IdType="pmc">PMC9833089</ArticleId><ArticleId IdType="pubmed">36379209</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>